Two-year results of the MERLOT trial showed no benefit of epimacular brachytherapy as an adjunct to anti-VEGF injections. In fact, the combined therapy group had worse results overall compared with the ranibizumab monotherapy group.
The attempt to combine anti-VEGF injections with epimacular brachytherapy (EMB) was driven by the hypothesis that targeted radiation might help reduce the overall number of injections without sacrificing visual acuity outcomes.
One-year results did not support the use of EMB. However, because the full effect of radiation and radiation damage takes time to manifest,
Uncategorized